Orbimed Advisors LLC Passage Bio, Inc. Transaction History
Orbimed Advisors LLC
- $2.8 Billion
- Q2 2025
A detailed history of Orbimed Advisors LLC transactions in Passage Bio, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 6,055,300 shares of PASG stock, worth $45.7 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
6,055,300
Previous 7,034,626
13.92%
Holding current value
$45.7 Million
Previous $2.46 Million
1.62%
% of portfolio
0.09%
Previous 0.08%
Shares
8 transactions
Others Institutions Holding PASG
# of Institutions
40Shares Held
35.2MCall Options Held
40.5KPut Options Held
0-
Lynx1 Capital Management LP San Juan, PR9.26MShares$69.8 Million1.1% of portfolio
-
Vestal Point Capital, LP New York, NY6.1MShares$46 Million0.13% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$18.8 Million2.97% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.46MShares$18.5 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.04MShares$15.4 Million0.0% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $411M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...